Join Richmond Pharmacology next month for the DIA Cardiovascular Safety and State-of-the-art Development Issues meeting taking place 17 to 18 April 2012 in Washington.The meeting will address present issues surrounding Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity during a series of debate-style presentations from international industry, academic, and regulatory speakers.Dr Jorg Taubel's current research is concerned with the cardiovascular effects of meals, insulin and C-peptide in Caucasian and Japanese populations. He will be presenting some of his most recent findings on Day 2 (18 Apr 2012), covering the following topics of discussion:Session 6, CV Safety Track at 10h30:
- Moxifloxacin effect on the QTc interval in fed and fasted states in Thorough QT studies
Session 4, Diabetes Track at 11h00:
- Insulin does not prolong the QT interval in thorough QT studies performed in healthy volunteers
For further information on Richmond Pharmacology�s specialist Cardiovascular Safety expertise or to request a copy of our latest TQT publication, contact a member of our Business Development team today. Alternatively we hope to see you in the US next month!